ALK-Abelló B Aktie Logo
DK0061802139
A3DHX9
ALK-B.CO

ALK-Abelló B Aktie

Forecast

Buy
  1
Hold
  0
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • ALK-Abelló beats Q4 expectations and proposes dividend

    ALK-Abelló reports Q4 revenue of DKK 1.73bn (3% above consensus) and EBIT of DKK 387m (5% above consensus). The EBIT margin rose to 22.3%, but net profit fell short of expectations due to higher taxes. The company proposes a dividend of DKK 1.60 per share for the first time since 2017 and expects 2026 revenue growth of 11–15% (DKK 6.9–7.2bn) with an EBIT margin of around 25%. ALK-Abelló also announced the resignation of its head of research & development and has begun the search for a successor. » More on de.investing.com


  • Alk-Abello A-S discloses quarterly figures for end of December

    Alk-Abello A-S reports on the quarter to 31.12.2025 on 20.02.2026. One analyst expects EPS of 1.30 DKK versus 0.770 DKK in the year-ago quarter. Four analysts see revenue at an average of 1.71 billion DKK, up 13.81 percent from 1.50 billion DKK. For the fiscal year analysts on average forecast EPS of 5.63 DKK (prior year 3.68 DKK) on revenue of 6.27 billion DKK (prior year 5.54 billion DKK). » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, ALK-Abelló B Aktie has already paid €0.21 in dividends. The last payout was in March.

Financials

In the last quarter, ALK-Abelló B Aktie had revenue of €230.31M and net profit of €47.26M

(EUR) September 2026
YoY
Revenue 230.31M 12.36%
Gross profit 156.15M 11.75%
Net profit 47.26M 12.35%
EBITDA 72.59M 6.25%

Fundamentals

Metric Value
Market capitalization
€6.7B
Number of shares
201.62M
52-week high/low
€37.01 - €27.77
Dividend yield
0.64%
Dividends TTM
€0.21
Beta
0.71
P/E ratio
38.74
PEG ratio
1.42
P/B ratio
7.48
P/S ratio
7.70

Company profile

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

Name
ALK-Abelló B Aktie
CEO
Peter Halling
Headquarters Horsholm, cr
Denmark
Website
Sector
Health Care
Industry
Pharmaceuticals
IPO
03/10/2000
Employees 2,721

Ticker symbols

Exchange Symbol
Nasdaq Copenhagen
ALK-B.CO
Pnk
AKBLF
Copenhagen
ALK B.CO
Frankfurt
4AJ0.F
Düsseldorf
4AJ0.DU
London
0OIR.L
München
4AJ0.MU
🍪

Parqet  uses cookies. Learn more